Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation
Open Access
- 24 May 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Experimental & Molecular Medicine
- Vol. 52 (5), 762-771
- https://doi.org/10.1038/s12276-020-0442-9
Abstract
Cancer: Phosphorylating enzyme may provide therapeutic target Better understanding of the roles played by a protein kinase, an enzyme that adds phosphate groups to other molecules, in healthy and diseased states may help scientists identify novel cancer treatments. Cyclin-dependent kinases (CDKs) are a family of protein kinases crucial to cell cycling and gene expression. CDK12 can activate and modulate cancer-related gene expression, but, according to a review by Seung Hyuk Choi and colleagues at the Salk Institute for Biological Studies in La Jolla, USA, further investigations into its exact functioning and control mechanisms are required. CDK12 mutations are frequently found in aggressive breast and ovarian cancers, while loss of CDK12 function results in abnormal expression of DNA damage response genes and genome instability. CDK12 may also regulate drug resistance in cancer cells. The team suggests that therapies targeting CDK12 are worth exploring. Cyclin-dependent kinases (CDKs) play critical roles in cell cycle progression and gene expression regulation. In human cancer, transcription-associated CDKs can activate oncogenic gene expression programs, whereas cell cycle-regulatory CDKs mainly induce uncontrolled proliferation. Cyclin-dependent kinase 12 (CDK12) belongs to the CDK family of serine/threonine kinases and has been recently found to have multiple roles in gene expression regulation and tumorigenesis. Originally, CDK12 was thought to be one of the transcription-associated CDKs, acting with its cyclin partner Cyclin K to promote the phosphorylation of the C-terminal domain (CTD) of RNA polymerase II and induce transcription elongation. However, recent studies have demonstrated that CDK12 also controls multiple gene expression processes, including transcription termination, mRNA splicing, and translation. Most importantly, CDK12 mutations are frequently found in human tumors. Loss of CDK12 function causes defective expression of DNA damage response (DDR) genes, which eventually results in genome instability, a hallmark of human cancer. Here, we discuss the diverse roles of CDK12 in gene expression regulation and human cancer, focusing on newly identified CDK12 kinase functions in cellular processes and highlighting CDK12 as a promising therapeutic target for human cancer treatment.This publication has 60 references indexed in Scilit:
- Interaction of Cyclin-Dependent Kinase 12/CrkRS with Cyclin K1 Is Required for the Phosphorylation of the C-Terminal Domain of RNA Polymerase IIMolecular and Cellular Biology, 2012
- Functional genomics identifies therapeutic targets for MYC-driven cancerProceedings of the National Academy of Sciences of the United States of America, 2012
- The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genesGenes & Development, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1Genes & Development, 2010
- Chemical-genomic dissection of the CTD codeNature Structural & Molecular Biology, 2010
- Ctk1 promotes dissociation of basal transcription factors from elongating RNA polymerase IIThe EMBO Journal, 2009
- CDK13, a New Potential Human Immunodeficiency Virus Type 1 Inhibitory Factor Regulating Viral mRNA SplicingJournal of Virology, 2008
- Serine-7 of the RNA Polymerase II CTD Is Specifically Required for snRNA Gene ExpressionScience, 2007
- The RNA polymerase II CTD kinase Ctk1 functions in translation elongationGenes & Development, 2007